Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance.

ABSTRACT: IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG.MethodsA retrospective review of the health records of patients who received palonosetron between 1 July 2019 and 30 June 2020 was undertaken. Details of palonosetron use, antiemetic r

SUBMITTER: Ames M 

PROVIDER: S-EPMC11898370 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature